Amount Raised
$20 Million
Round Type
Series B
GermantownBiotechnologyHealth CareScience And EngineeringInvestors
Description
Maryland-based biotech company Deka Biosciences ("Deka") today announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm. The proceeds of the financing will support the advancement of Deka's pipeline and drug product manufacturing as they continue clinical trials following the receipt of a notice to proceed letter from the FDA for their investigational new drug (IND) application to evaluate DK210 (EGFR). Additionally, Detlev Biniszkiewicz, Ph.D. of MPM-BioImpact, will join the Deka board.
Quick answer
Deka Biosciences, Inc. raised $20 Million in a Series B round, dated September 28, 2023. Investors: Detlev Biniszkiewicz, Atem Capital And Ceo John Mumm, Plains Ventures, Amana Investments, Alexandria Venture Investments, Viva Bio Innovator, O Bio and Leaps By Bayer. Deka Biosciences, Inc. is based in Germantown, Illinois, United States.
- How much did Deka Biosciences, Inc. raise?
- Deka Biosciences, Inc. raised $20 Million in a Series B round on September 28, 2023.
- Who invested in Deka Biosciences, Inc?
- Detlev Biniszkiewicz, Atem Capital And Ceo John Mumm, Plains Ventures, Amana Investments, Alexandria Venture Investments, Viva Bio Innovator, O Bio and Leaps By Bayer are named as investors in this round.
- What does Deka Biosciences, Inc. do?
- Deka is an early-stage biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn's, psoriasis, rheumatoid arthritis and sepsis.
- Where is Deka Biosciences, Inc. based and how big is it?
- Deka Biosciences, Inc. is based in Germantown, Illinois, United States.
- Who are the decision-makers at Deka Biosciences, Inc?
- Fundz holds 1 contact at Deka Biosciences, Inc., including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Deka Biosciences, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Zephyr AI, Inc. raised $111M on October 27, 2023.
- Trait Biosciences Inc. raised an undisclosed amount (Funding Round) on October 11, 2023.
- Specific Biologics raised an undisclosed amount on October 10, 2023.
- RedHill Biopharma Ltd raised $4M (Seed) on September 28, 2023.
- Geneos Therapeutics raised an undisclosed amount (Series A) on September 27, 2023.
- Trait Biosciences Inc. raised $3.7M (Series A) on September 12, 2023.
Who to call at Deka Biosciences, Inc., and when
A new round usually means Deka Biosciences, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Deka Biosciences, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Deka Biosciences, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Deka Biosciences, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Deka Biosciences, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansDeka Biosciences, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.